Taken together, we have successfully established a human SMN2 reporter for future drug discovery and identified the potential therapeutic value of cysteine protease inhibitors in treating SMA via stabilizing SMN proteins. The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.